Results 241 to 250 of about 130,782 (308)

MEK 1/2 Inhibitor AS703988/MSC2015103B [PDF]

, 2020
openaire   +1 more source

Traditional Chinese Herbal Plant Penthorum chinense Pursh: Health Factors and Its Future Development

Food Science &Nutrition, Volume 14, Issue 4, April 2026.
This review expounds on the species, morphological characteristics, and distribution areas of Penthorum chinense Pursh, summarizes the active ingredients mainly including flavonoids in PCP and their extraction methods. It also pays particular attention to the pharmacological effects of PCP, such as liver protection, antioxidation, anti‐inflammation ...
Hui Zhang, Ning Zhang, Baoguo Sun
wiley   +1 more source

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.

JAMA Dermatol
Gross AM, Reid OH, Baldwin LA, Cannon A, Choo-Wosoba H, Steinberg SM, Lobbous M, Wolters PL, Pichard DC, Tibery CM, Dombi E, Derdak J, Widemann BC, Korf BR.   +13 more
europepmc   +1 more source

Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on <i>KRAS</i> or <i>BRAF</i> mutant colon cancer cells. [PDF]

Biochem Biophys Rep
Sato M, Yamamoto Y, Moriwaki T, Fukuda K, Tsuchiya K.   +4 more
europepmc   +1 more source

Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

Head &Neck, Volume 48, Issue 4, Page 932-940, April 2026.
ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue, Tolulope Adeyelu, Harris Krause, Andrew Elliott, Ranee Mehra, Heloisa Soares, Emil Lou, Ari Vanderwalde, David Spetzler, Dara Bracken‐Clarke, Nyall R. London Jr., James L. Gulley, Charalampos S. Floudas   +12 more
wiley   +1 more source

The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models. [PDF]

Transl Psychiatry
Raut SB, Joly F, Haass NK, Eri R, Canales JJ, Benedek DM, Ursano RJ, Johnson LR.   +7 more
europepmc   +1 more source

Anti‐Cancer Effect of a New 5‐FU Derivative Containing Triazole‐Bearing Mannose (5‐FUD‐MAN) Against Human Breast Cancer Cells Through LC3B‐Mediated Cell Death

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 4, April 2026.
The anticancer activity of 5‐FU modified with mannose containing 1,2,3‐triazole compound in MCF‐7 breast cancer cells were revealed in this study. While 5‐FU caused cytotoxicity in both cancerous and healthy cells, 5‐FUD‐Man showed selective cytotoxicity.
Ebru Şanci, Azada Aliyeva, Buket Bakan, Mustafa Özkaraca, Erkan Halay, Kadir Ay, Tamer Karayildirim, N. Ulku Karabay Yavasoglu   +7 more
wiley   +1 more source

IL‐15 Links Muscle–Kidney Crosstalk to Preserving Podocyte Mitochondrial Fusion and Attenuating Diabetic Nephropathy

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Objectives High glucose induces mitochondrial dysfunction in podocytes, contributing to the development of diabetic nephropathy (DN). There is increasing evidence that muscles play a protective role by secreting myokines into the kidneys. Here, we investigated how skeletal muscle influences podocyte health via muscle–kidney crosstalk.
Yin Li, Jialing Rao, Weiyan Lai, Yuxiang Sun, Hongchun Lin, Jun Zhang, Zengchun Ye, Zhaoyong Hu, Hui Peng   +8 more
wiley   +1 more source

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. [PDF]

Breast Cancer Res Treat
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B.   +23 more
europepmc   +1 more source

Selumetinib as an Effective Therapy of Histiocytic Sarcoma Evolving From a B‐Cell Acute Lymphoblastic Leukaemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Histiocytic sarcoma (HS) is a rare neoplasm derived from non‐Langerhans histiocytic cells, exceptionally arising from B‐ALL. Methods We present the case of a child with high‐risk B‐ALL with PAX5 P80R mutation. Results Despite initial remission, a chemoresistant paravertebral mass was identified as HS.
Laetitia Largeaud, Charlotte Syrykh, Julie Vial, Alban Canali, Isabelle Luquet, François Vergez, Stéphanie Dufrechou, Naïs Prade, André Baruchel, Bastien Gerby, Marie Nolla, Eric Delabesse, Marlène Pasquet   +12 more
wiley   +1 more source